These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 16203282)
1. Factors associated with disease progression in patients with gastrointestinal stromal tumors in the pre-imatinib era. Iesalnieks I; Rümmele P; Dietmaier W; Jantsch T; Zülke C; Schlitt HJ; Hofstädter F; Anthuber M Am J Clin Pathol; 2005 Nov; 124(5):740-8. PubMed ID: 16203282 [TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases. Miettinen M; Sobin LH; Lasota J Am J Surg Pathol; 2009 Sep; 33(9):1267-75. PubMed ID: 19440146 [TBL] [Abstract][Full Text] [Related]
3. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining. Lee HE; Kim MA; Lee HS; Lee BL; Kim WH J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383 [TBL] [Abstract][Full Text] [Related]
4. Kinase mutations and efficacy of imatinib in Korean patients with advanced gastrointestinal stromal tumors. Kim TW; Ryu MH; Lee H; Sym SJ; Lee JL; Chang HM; Park YS; Lee KH; Kang WK; Shin DB; Bang YJ; Lee JS; Kang YK Oncologist; 2009 May; 14(5):540-7. PubMed ID: 19411681 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Mussi C; Schildhaus HU; Gronchi A; Wardelmann E; Hohenberger P Clin Cancer Res; 2008 Jul; 14(14):4550-5. PubMed ID: 18628470 [TBL] [Abstract][Full Text] [Related]
6. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors. Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300 [TBL] [Abstract][Full Text] [Related]
7. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor. Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK Oncology; 2009; 76(5):326-32. PubMed ID: 19307738 [TBL] [Abstract][Full Text] [Related]
8. The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated. Penzel R; Aulmann S; Moock M; Schwarzbach M; Rieker RJ; Mechtersheimer G J Clin Pathol; 2005 Jun; 58(6):634-9. PubMed ID: 15917417 [TBL] [Abstract][Full Text] [Related]
9. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital. Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905 [TBL] [Abstract][Full Text] [Related]
10. The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor (GIST). Du CY; Shi YQ; Zhou Y; Fu H; Zhao G J Surg Oncol; 2008 Sep; 98(3):175-8. PubMed ID: 18618605 [TBL] [Abstract][Full Text] [Related]
11. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression. Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121 [TBL] [Abstract][Full Text] [Related]
15. Spectrum and prognostication of KIT and PDGFRA mutation in gastrointestinal stromal tumors. Tzen CY; Wang MN; Mau BL Eur J Surg Oncol; 2008 May; 34(5):563-8. PubMed ID: 17532173 [TBL] [Abstract][Full Text] [Related]
16. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors. Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095 [TBL] [Abstract][Full Text] [Related]
17. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Lasota J; Miettinen M Histopathology; 2008 Sep; 53(3):245-66. PubMed ID: 18312355 [TBL] [Abstract][Full Text] [Related]
18. Platelet-derived growth factor receptor family mutations in gastrointestinal stromal tumours. Sihto H; Franssila K; Tanner M; Vasama-Nolvi C; Sarlomo-Rikala M; Nupponen NN; Joensuu H; Isola J Scand J Gastroenterol; 2006 Jul; 41(7):805-11. PubMed ID: 16785193 [TBL] [Abstract][Full Text] [Related]
19. Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy. Keun Park C; Lee EJ; Kim M; Lim HY; Choi DI; Noh JH; Sohn TS; Kim S; Kim MJ; Lee HK; Kim KM Ann Surg; 2008 Jun; 247(6):1011-8. PubMed ID: 18520229 [TBL] [Abstract][Full Text] [Related]